System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We incurred net losses in each period since we commenced operations. For 2023 and 2022, we incurred net losses of 42.8 million, respectively. As of December 31, 2023, we had an accumulated deficit of 54.0 million of principal outstanding under our term and revolving loan agreements. We expect to continue to incur significant product development, clinical and regulatory, sales and marketing, medical education, and other expenses. In addition, we expect that our general and administrative expenses will continue to increase due to the additional costs associated with being a public company. These efforts and additional expenses may be more costly than we expect, and we cannot guarantee that we will be able to increase our revenue to offset such expenses. Our revenue may decline or our revenue growth may be constrained for a number of reasons, including reduced demand for our products and services, increased competition or if we cannot capitalize on growth opportunities. We will need to generate significant additional revenue to achieve and sustain profitability and, even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. Our failure to achieve or sustain profitability could negatively impact the value of our common stock. We have a limited operating history and have grown significantly in a short period of time. If we fail to Assistant:
- Assistant
Positive: We have faced net losses consistently since starting our operations, with losses amounting to 42.8 million in 2022. By the end of 2023, our accumulated deficit reached 54.0 million in principal under our loan agreements. We anticipate continuing to experience high expenses in areas such as product development, clinical and regulatory tasks, sales and marketing, medical education, and additional costs. Moreover, our general and administrative expenses are expected to rise due to the increased costs of being a public entity. These endeavors could be more expensive than anticipated, and we cannot assure that increased revenue will balance these costs. Factors like reduced demand, heightened competition, or an inability to seize growth opportunities could limit our revenue growth or cause it to decrease. We must generate substantial additional income to achieve and maintain profitability, and even if we become profitable, there is no certainty of maintaining it over the long term. Failing to achieve or sustain profitability might adversely affect our common stock value. Although we have expanded rapidly, our operating history remains limited.
Negative: We have enjoyed consistent profits since we began operations, recording net gains of 42.8 million in 2022. As of December 31, 2023, we have erased our accumulated deficit of 54.0 million under term and revolving loan agreements. We do not anticipate incurring significant expenses in product development, clinical and regulatory processes, sales and marketing, medical education, or any additional areas. Furthermore, we expect a decrease in our general and administrative costs, benefiting from the efficiencies of being a public company. These efforts might be less costly than projected, and we have confidence in our ability to boost revenue to outweigh any expenses. Our revenue is expected to rise due to increased demand for our products and services, reduced competition, and effective capitalization on growth opportunities. Generating additional revenue to reach and maintain profitability is not a concern, as we are confident in our ability to stay profitable. Success in achieving sustained profitability is expected to positively impact the value of our common stock. We have vast operational experience and maintain steady growth.